Ammonia is generated from intestinal nitrogen metabolism, including bacterial urease activity and glutamine metabolism in the gut.
← LCCH Physiology
Module 02
How does ammonia become a brain problem?
Track nitrogen from the gut to periportal urea synthesis, pericentral glutamine scavenging, portosystemic escape and the astrocyte response.
Clinical frame
The organising problem.
Ammonia is central to the biology of hepatic encephalopathy, but encephalopathy is not a simple one-variable toxicity syndrome. Inflammation, hyponatraemia, cerebral energy metabolism and precipitating illness modify the clinical phenotype.
Mechanism · Gut production
Nitrogen enters the portal circulation
01Protein / urea nitrogen
02Gut metabolism
03NH₃ / NH₄⁺
04Portal delivery
Portal blood normally delivers this nitrogen load directly to the liver for high-capacity detoxification.
GI bleeding, constipation and increased nitrogen delivery can increase the burden reaching the portal circulation.
Step 1 of 6
Change the route, the capacity or the brain’s vulnerability.
Compare three ways the gut–liver–muscle–brain system can become unstable.
Increase shunting. A large portosystemic shunt diverts blood around functioning hepatocytes.
- 01
Gut nitrogen
ReferenceUsual nitrogen load
Selected scenarioNeed not increase
- 02
Hepatic handling
ReferenceUrea + scavenging
Selected scenarioLess blood reaches hepatocytes
- 03
Systemic exposure
ReferenceLimited ammonia escape
Selected scenarioMore portal nitrogen bypasses liver
- 04
Cerebral context
ReferenceOsmotic homeostasis
Selected scenarioHE susceptibility can rise
Why this happens
The liver can only extract substrate delivered to it. Bypass raises systemic exposure even when the remaining hepatocytes retain useful metabolic capacity.
What to look for
Recurrent HE can be disproportionate to the apparent degree of synthetic dysfunction.
Limit of the model A shunt increases susceptibility; it does not make every episode of confusion hepatic encephalopathy.
Sources and context: EASL HE guideline (2022) ↗EASL ALF guideline (2017) ↗
Go deeper
Mechanisms beneath the model.
Open the topics you need. Keep several explanations visible to compare mechanisms.
Evidence key: Established: broadly supported. Nuanced: context affects interpretation. Evolving: evidence or definitions remain unsettled. These labels describe physiological certainty, not a formal GRADE rating.
01ZonationTwo hepatic ammonia systems work in seriesEstablished
Periportal urea synthesis provides high-capacity disposal, while pericentral glutamine synthesis scavenges residual ammonia at low concentrations.
- Metabolic zonation is central to normal ammonia homeostasis.
- Portosystemic shunting bypasses both systems.
- Skeletal muscle can become an important extrahepatic ammonia sink in cirrhosis.
02BrainAstrocyte swelling is only part of the storyNuanced
Glutamine accumulation, mitochondrial dysfunction, oxidative stress, altered neurotransmission and inflammation all contribute to the cerebral phenotype.
- Acute and chronic liver failure are not identical brain states.
- Rapid ammonia exposure is particularly important in ALF.
- Clinical grade and venous ammonia do not map perfectly one-to-one in cirrhosis.
03MuscleSarcopenia removes an ammonia-buffering organEstablished
Skeletal muscle can metabolise ammonia via glutamine synthesis; severe muscle loss reduces this compensatory capacity.
- Muscle and liver nitrogen metabolism are linked.
- Hyperammonaemia may itself promote muscle catabolism.
- This creates a clinically relevant liver-muscle-brain axis.
04NitrogenDetoxification can move nitrogen rather than eliminate itEstablished
Urea synthesis packages nitrogen for renal excretion. Glutamine synthesis incorporates ammonia into an amino acid; that is a useful buffering step, but glutamine can subsequently release ammonia when metabolised elsewhere. A muscle ammonia sink therefore forms part of an inter-organ nitrogen cycle.
- Periportal urea synthesis provides high-capacity disposal; the smaller pericentral glutamine-synthetase population scavenges residual ammonia.
- Shunting changes delivery to these systems. Hepatocyte dysfunction reduces their capacity. Both can occur together.
- Sarcopenia removes extrahepatic buffering capacity. This helps explain the physiological importance of preserving muscle in chronic liver disease.
05BrainTime course changes the brain’s responseNuanced
Astrocytes incorporate ammonia into glutamine. The associated osmotic and metabolic stress is modified by inflammation, sodium and the speed of exposure. Chronic hyperammonaemia allows osmotic adaptation; abrupt liver failure can overwhelm this before adaptation occurs.
- The same measured ammonia concentration need not imply the same cerebral risk in ALF and longstanding cirrhosis.
- In cirrhosis, a raised ammonia does not establish the cause or grade of encephalopathy. A normal result should prompt diagnostic reconsideration.
- In ALF, ammonia belongs within a broader assessment of cerebral oedema risk, including neurological course, renal function and systemic inflammation.
Interventions
What are we trying to change?
Therapy makes more sense when its physiological target is explicit. These are mechanism summaries, not prescribing guidance.
TargetGut ammonia generation / absorption
Lactulose
Changes colonic environment and increases nitrogen excretion while also treating constipation.
TargetGut microbiome function
Rifaximin
Reduces recurrent overt HE when used in appropriate patients, usually alongside lactulose.
TargetInflammatory / nitrogen / drug trigger
Treat precipitant
Correcting infection, bleeding, constipation, sedatives or electrolyte disturbance can rapidly improve brain function.
TargetDetoxification and shunting physiology
Transplantation
Restores hepatic ammonia handling when irreversible liver failure is the driver.
Apply the mechanism.
What not to conclude.
- Treating the ammonia number rather than the patient.
- Ignoring a normal ammonia result: it should prompt reconsideration of HE and a search for alternative causes.
- Ignoring sodium, infection, sedatives or hypercapnia as cerebral modifiers.
- Forgetting sarcopenia and spontaneous shunts in recurrent HE.
Four things to keep.
- Ammonia homeostasis is zonated across the hepatic lobule.
- Shunting and loss of hepatocyte function both increase systemic exposure.
- The astrocyte is a key target, but inflammation and osmotic context determine vulnerability.
- HE is a systems problem spanning gut, liver, muscle and brain.
Evidence & current guidance
Where the physiology meets current practice.
Clinical criteria and treatment recommendations change faster than core physiology. This layer keeps the module tied to current consensus and primary evidence.
In cirrhosis, hepatic encephalopathy remains a clinical diagnosis
Ammonia is biologically central to hepatic encephalopathy, but a raised blood ammonia concentration alone does not diagnose, stage or reliably grade overt HE in chronic liver disease. A normal result should instead make the clinician reconsider the diagnosis and look harder for a mimic.
- Do not treat an isolated ammonia number as though it were the neurological examination.
- Pre-analytical handling, sampling site and laboratory method can materially affect measured ammonia.
- Serial ammonia values are not a substitute for clinical response in cirrhotic HE.
- Delirium, sedatives, seizures, hypercapnia, hypoglycaemia, sepsis and intracranial pathology remain important competing diagnoses on ICU.
The same molecule has a different clinical meaning in ALF
In acute liver failure, rapid loss of hepatic ammonia clearance occurs before the brain has had time to develop the osmotic adaptations seen in chronic disease. Arterial hyperammonaemia therefore has much greater relevance to cerebral oedema and intracranial hypertension risk than it does to grading HE in stable cirrhosis.
- Astrocytic conversion of ammonia to glutamine contributes to cytotoxic swelling and disturbed cerebral osmoregulation.
- An arterial ammonia concentration above about 150 μmol/L is a recognised risk marker for intracranial hypertension in ALF, not an absolute threshold for herniation.
- Systemic inflammation, renal failure, hyponatraemia and cerebral blood-flow abnormalities modify the risk.
- A cirrhotic patient with chronic hyperammonaemia and an ALF patient with rapidly rising ammonia should not be conceptualised as the same neurological syndrome.
Reduce nitrogen burden, treat the precipitant and protect the brain
For overt HE in cirrhosis, treatment starts with identifying and correcting precipitants. Lactulose remains first-line therapy; rifaximin is used particularly to reduce recurrence. The ICU approach must also address airway protection, infection, sodium and carbon dioxide, sedative exposure, seizures and other cerebral stressors.
- GI bleeding, constipation, infection, dehydration, electrolyte disturbance and psychoactive drugs are common precipitants.
- Lactulose should improve nitrogen disposal without causing excessive diarrhoea, hypovolaemia or electrolyte loss.
- Rifaximin reduces recurrent overt HE in appropriate patients, usually as an adjunct rather than a replacement for precipitant control.
- In ALF with severe hyperammonaemia, organ support — including early continuous renal replacement therapy in selected patients — may be used as part of a broader neuroprotective strategy.
The phenotype emerges from a gut–liver–muscle–brain system
Ammonia is necessary to understand HE but insufficient to explain every fluctuation in consciousness. Portosystemic shunting, skeletal-muscle ammonia handling, inflammation, astrocyte osmotic adaptation, neurotransmission and electrolyte status all modify cerebral vulnerability.
- Sarcopenia reduces an important extrahepatic route for ammonia incorporation into glutamine.
- Large spontaneous portosystemic shunts can drive recurrent HE even when hepatocyte function is relatively preserved.
- Inflammation can amplify the cerebral effect of a given ammonia burden.
- This is why clinical HE severity and venous ammonia concentration often correlate imperfectly in cirrhosis.
Key sourcesPrimary guidance and landmark evidence
Reviewed 12 September 2026 · next scheduled review September 2027EASL Clinical Practice Guidelines on the management of hepatic encephalopathyEuropean Association for the Study of the Liver. J Hepatol. 2022;77:807–824. doi:10.1016/j.jhep.2022.06.001.
Current European clinical-practice guideline covering definition, diagnosis, differential diagnosis, treatment and prevention of HE in chronic liver disease.
View source ↗Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by AASLD and EASLVilstrup H, et al. Hepatology. 2014;60:715–735. doi:10.1002/hep.27210.Joint AASLD/EASL guideline establishing the clinical diagnostic framework and the limited diagnostic value of an isolated ammonia concentration in chronic liver disease.
View source ↗EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failureEuropean Association for the Study of the Liver. J Hepatol. 2017;66:1047–1081. doi:10.1016/j.jhep.2016.12.003.Acute liver failure guidance underpinning the distinct relationship between hyperammonaemia, cerebral oedema and intracranial hypertension in ALF.
View source ↗The Story of Ammonia in Liver Disease: An Unraveling ContinuumAnand AC, Acharya SK. J Clin Exp Hepatol. 2024;14:101361. doi:10.1016/j.jceh.2024.101361.Recent review of ammonia production, hepatic and extrahepatic handling, measurement limitations and its differing relevance across liver-failure syndromes.
View source ↗Review policy: each module is reviewed at least annually and sooner after a major guideline, consensus statement or practice-changing study. A review date indicates editorial review, not that every linked source is open access.